Last updated on June 2018

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy


Brief description of study

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Clinical Study Identifier: NCT02717611

Contact Investigators or Research Sites near you

Start Over

Jeannine Madere

Majadahonda, Spain